bioAffinity Technologies Closes $4M Stock Offering via WallachBeth

WallachBeth Capital LLC announced the closing of a $4 million registered direct financing of common stock for bioAffinity Technologies, Inc., a Nasdaq-listed biotechnology company developing noninvasive healthcare solutions. The transaction included a concurrent private placement and was priced at-the-market in accordance with Nasdaq rules.

bioAffinity Technologies trades on Nasdaq under the ticker symbols BIAF and BIAFW. The company focuses on noninvasive diagnostic and healthcare technology, positioning itself within a segment of the biotech sector that has attracted sustained investor interest in recent years.

Read more Aon to Report Q3 2026 Earnings on October 28 →

WallachBeth Capital, headquartered in Jersey City, N.J., served as the capital markets advisor and placement agent for the deal. The firm describes itself as a leading provider of capital markets and institutional execution services, frequently arranging financings for small- and mid-cap companies seeking access to public equity markets.

Registered direct offerings paired with concurrent private placements have become a common structure for smaller Nasdaq-listed biotechs, allowing companies to raise capital efficiently while limiting dilution and maintaining compliance with exchange listing standards. Pricing at-the-market under Nasdaq rules means the offering price was tied to the prevailing market price at the time of the transaction rather than set at a negotiated discount.

Continue reading at Banking & Financial Services.